Introduction
============

GABA (γ-aminobutyric acid) mediates fast inhibitory transmission by interacting with GABA type A (GABA~A~) receptors in the central nervous system. These ligand-gated ion channels are assembled from individual subunits forming a pentameric structure. A total of 19 isoforms of mammalian GABA~A~ receptor subunits have been cloned: α1--6, β1--3, γ1--3, δ, ɛ, π, ρ1--3 and θ ([Barnard *et al*., 1998](#bib5){ref-type="other"}; [Simon *et al*., 2004](#bib38){ref-type="other"}). The subunit composition determines GABA sensitivity, sensitivity for benzodiazepines (BZDs), barbiturates, neurosteroids and anaesthetics ([Sieghart, 1995](#bib33){ref-type="other"}; [Hevers and Luddens, 1998](#bib22){ref-type="other"}; [Sigel, 2002](#bib34){ref-type="other"}; [Ernst *et al*., 2003](#bib17){ref-type="other"}, [2005](#bib18){ref-type="other"}) and also the gating properties of GABA~A~ receptors ([Feng *et al*., 2004](#bib19){ref-type="other"}; [Boileau *et al*., 2003](#bib12){ref-type="other"}, [2005](#bib13){ref-type="other"}). The N-terminal parts of α- and β-subunits participate in the formation of the two agonist sites ([Sigel *et al*., 1992](#bib36){ref-type="other"}; [Amin and Weiss, 1993](#bib2){ref-type="other"}; [Boileau and Czajkowski, 1999](#bib11){ref-type="other"}; [Wagner and Czajkowski, 2001](#bib40){ref-type="other"}; [Newell and Czajkowski, 2003](#bib30){ref-type="other"}). GABA binding to these sites leads to pore opening.

BZDs interact with amino-acid residues located at the interface between α- and γ-subunits ([Macdonald and Barker, 1978](#bib27){ref-type="other"}; [Sigel and Buhr, 1997](#bib37){ref-type="other"}). These drugs allosterically modulate activation of GABA~A~ receptors either by increasing apparent affinity of at least one agonist-binding site ([Gallager and Tallman, 1983](#bib21){ref-type="other"}; [Serfozo and Cash, 1992](#bib32){ref-type="other"}; [Lavoie and Twyman, 1996](#bib26){ref-type="other"}) or affecting the pore opening ([Baur and Sigel, 2005](#bib9){ref-type="other"}). GABA~A~ receptors carry two GABA-binding sites at the respective αβ interfaces (see [Twyman *et al*., 1990](#bib39){ref-type="other"}). By selective disruption of the one or the other of these sites in concatenated GABA~A~ receptors, it recently has been demonstrated ([Baur and Sigel, 2005](#bib9){ref-type="other"}) that chloride currents were potentiated by diazepam in both cases.

Heterologous expression systems are the basis for drug development and pharmacological characterization of different GABA~A~ receptor subtypes. Transfection of mammalian cells or cRNA injection into *Xenopus* oocytes with α1, β2 and γ2 subunits may, however, result in different mixtures of α1β2 and α1β2γ2 receptors ([Baumann *et al*., 2001](#bib6){ref-type="other"}; [Boileau *et al*., 2002](#bib10){ref-type="other"}, [2003](#bib12){ref-type="other"}), which complicates the unequivocal estimation of potencies and efficiencies of BZDs in heterologous expression systems. This problem can be partially overcome by injecting larger amounts of γ2 subunit cRNA ([Boileau *et al*., 2002](#bib10){ref-type="other"}) or, alternatively, by making use of concatenated GABA~A~ receptor subunits ([Baumann *et al*., 2002](#bib7){ref-type="other"}; [Minier and Sigel, 2004](#bib29){ref-type="other"}; [Boileau *et al*., 2005](#bib13){ref-type="other"}).

We have previously reported that different efficiencies of BZDs to enhance chloride currents through GABA~A~ receptors comprising γ1 or γ2S subunits are related to their ability to shift the GABA concentration--response curves towards higher GABA sensitivities ([Khom *et al*., 2006](#bib24){ref-type="other"}). Here we analyse the relation between γ-induced inhibition of GABA sensitivity and GABA-induced chloride current (*I*~GABA~) potentiation by three BZDs (triazolam, clotiazepam and midazolam) in oocytes expressing different populations of α1β2 and α1β2γ2S(γ1) subunit receptors. Correlation analysis yielded regression lines with slope factors reflecting higher drug efficiency in γ2S than in γ1 subunit-comprising receptors. GABA sensitivity and *I*~GABA~ potentiation of concatenated subunits (γ2-β2-α1 and β2-α1) fitted the regression lines of non-concatenated receptors supporting the hypothesis that their lower GABA sensitivity is due to complete γ2S incorporation (rather than forced subunit arrangement). A simulation supports the hypothesis that even under conditions where a higher ratio of γ2S cRNA relative to α1 and β2 cRNA is injected oocytes contain a significant population of α1β2 receptors.

Smaller slope factors of the regression lines were estimated for oocytes expressing receptors with lower GABA sensitivity (mutant β2-R207C; [Wagner *et al*., 2004](#bib41){ref-type="other"}).

Materials and methods
=====================

Expression of GABA~A~ receptors
-------------------------------

Stage V--VI oocytes from *Xenopus laevis* were prepared and cRNA was injected as previously described by [Khom *et al*. (2006)](#bib24){ref-type="other"}. Female *X. laevis* (NASCO, WI, USA) were anaesthetized by exposing them for 15 min to a 0.2% MS-222 (methanesulphonate salt of 3-aminobenzoic acid ethyl ester; Sandoz, Germany) solution before surgically removing parts of the ovaries. Follicle membranes from isolated oocytes were enzymically digested with 2 mg mL^−1^ collagenase (Type 1A; Sigma, Vienna, Germany). Synthesis of capped run-off poly(A^+^) cRNA transcripts was obtained from linearized cDNA templates (pCMV vector). At 1 day after enzymatic isolation, the oocytes were injected with 50 nL of water treated with diethylpyrocarbonate (Sigma) containing the different rat cRNAs at a concentration of approximately 300--3000 pg nL^−1^ per subunit. The amount of cRNA was determined by means of a NanoDrop ND-1000 (Kisker-Biotech, Steinfurt, Germany). To ensure expression of the γ-subunit with different incorporation in the case of α1β2γ1 and α1β2γ2S receptors cRNAs were mixed in a ratios: 1:1:1, 1:1:3 and 1:1:10. The double β2-23-α1 (β2-α1) and triple γ2-26-β2-23-α1 (γ2-β2-α1) concatemers (kindly provided by E Sigel) and the β2-R207C mutant (kindly provided by C Czajkowski) have been described previously ([Baumann *et al*., 2001](#bib6){ref-type="other"}, [2002](#bib7){ref-type="other"}; [Wagner *et al*., 2004](#bib41){ref-type="other"}). Oocytes were stored at 18 °C in ND96 solution ([Methfessel *et al*., 1986](#bib28){ref-type="other"}). Voltage clamp measurements were performed between days 1 and 5 after cRNA injection.

Two-microelectrode voltage clamp studies
----------------------------------------

Electrophysiological experiments were performed by the two-microelectrode voltage clamp method making use of a TURBO TEC 01C amplifier (npi electronic GmbH, Tamm, Germany) at a holding potential of −70 mV. The bath solution contained 90 m[M]{.smallcaps} NaCl, 1 m[M]{.smallcaps} KCl, 1 m[M]{.smallcaps} MgCl~2~, 1 m[M]{.smallcaps} CaCl~2~ and 5 m[M]{.smallcaps} HEPES (pH 7.4).

Perfusion system
----------------

GABA was applied by means of an automated fast perfusion system according to [Baburin *et al*. (2006)](#bib4){ref-type="other"}. To elicit *I*~GABA~ the chamber was perfused with 120 μL of GABA-containing solution at volume rates of 300 μL s^−1^. Duration of washout periods was extended from 3 to up to 20 min with increasing concentrations of applied GABA to account for slow recovery from increasing levels of desensitization (see [Khom *et al*., 2007](#bib25){ref-type="other"} for details).

Analysing concentration--response curves
----------------------------------------

Concentration--response curves were generated and the data were fitted by non-linear regression analysis using Origin software (OriginLab Corporation, Northampton, MA, USA). Data were fitted to the equation: , where EC~50~ is the concentration of the GABA that induces half-maximal GABA-evoked current and *n*~H~ is the Hill coefficient. Concentration--response data for each oocyte were normalized to the maximum control GABA current for that oocyte. Statistical significance was calculated using unpaired Student\'s *t*-test with a confidence interval of *P*\<0.05.

Calculation of EC~50~ and ΔEC~50~ of mixed population
-----------------------------------------------------

The EC~50~ values and BZD-induced shifts in GABA sensitivity in oocytes expressing mixed receptor populations (different fractions of high GABA sensitive α1β2 versus low-sensitive α1β2γ2S receptors) are described by the concentration--response curves for each receptor population by: and where *R*~αβ~ and *R*~αβγ~ are peak *I*~GABA~ currents (number of open channels in each population) at a given GABA concentration, *i*~αβ~ and *i*~αβγ~, amplitudes of single channel currents, *N*~αβ~ and *N*~αβγ~ are numbers of channels characterized by EC~50,αβ~ and EC~50,αβγ~, midpoints of concentration--response curves, *H*~αβ~ and *H*~αβγ~---Hill coefficients.

The total normalized *I*~GABA~ is a weighted sum of partial current responses: where *F* is the fraction (0\<*F*\<1) of current through γ-containing GABA~A~ receptors at saturating GABA concentrations: *F*=(*i*~αβγ~*N*~αβγ~)/(*i*~αβ~*N*~αβ~+*i*~αβγ~*N*~αβγ~).

Under-application of a saturating concentration of BZD the receptor population consists of two subpopulations:

\(1\) αβ receptors with unchanged EC~50,αβ~ and *H*~αβ~

and

\(2\) modulated *αβγ* receptors with enhanced GABA sensitivity (midpoint, EC~50,mod~ and Hill coefficient, *H*~mod~): The total current response is described now by: The apparent midpoints of the GABA concentration--response curves (EC~50~) for oocytes expressing a given fractions (*F*) of α1β2γ2S receptors and the shift of this curve (ΔEC~50~(BZD)) at saturating concentrations of triazolam, clotiazepam and midazolam can be obtained by varying the fractions (*F*) from 0 to 1 by maximum likelihood.

Chemicals
---------

Compounds were obtained from the following sources: triazolam (8-chloro-6-(2-chlorophenyl)-1-methyl-4H-1,2,4-triazolo\[4,3-a\]\[1,4\]benzodiazepine; Sigma), clotiazepam (5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-2H-thieno\[2,3-e\]\[1,4\]diazepin-2-one; Troponwerke, Köln, Germany), midazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo\[1,5-a\]\[1,4\]benzodiazepine; Hoffmann La Roche, Basel, Switzerland).

Results
=======

Modulation by BZDs of chloride currents through GABA~A~ receptors expressed in *Xenopus* oocytes is dependent on the incorporation of a γ-subunit ([Boileau *et al*., 2002](#bib10){ref-type="other"}). On the one hand injection of increasing amounts of γ-encoding cRNA (that is, α1:β2:γ2S ratios of 1:1:3 or 1:1:10) gradually reduces GABA sensitivity and, on the other hand, the increased fraction of α1β2γ2S receptors results in an increased *I*~GABA~ potentiation by BZDs. To quantify the relation between γ-subunit-mediated inhibition of GABA sensitivity and BZD action we have analysed modulation of GABA-induced chloride currents (*I*~GABA~) in a large population of oocytes injected with different mixtures (1:1:1, 1:1:3, 1:1:10) of wild-type or mutated α1, β2 and γ2S or γ1 GABA~A~ receptor subunits, or γ2-β2-α1/β2-α1 concatenated constructs. Triazolam, clotiazepam and midazolam were chosen because these drugs modulate GABA~A~ receptors incorporating γ2S and γ1 subunits that would allow us to compare their action at different efficiencies.

Modulation of *I*~GABA~ by BZDs in oocytes expressing variable ratios of α1β2 versus α1β2γ1 or α1β2γ2S receptors
----------------------------------------------------------------------------------------------------------------

[Figure 1a](#fig1){ref-type="fig"} illustrates the effect of triazolam on the concentration--response curves of *I*~GABA~ through GABA~A~ receptors in oocytes injected with different ratios of cRNAs encoding for α1, β2 and γ2S subunits. A saturating concentration (1 μ[M]{.smallcaps}) of triazolam shifted the GABA concentration--response curves leftwards without significant effects on the maximal response. Higher γ2S expression and thus, presumably higher γ2S incorporation resulted in reduced GABA sensitivity and larger triazolam-induced shifts of the GABA EC~50~ values (ΔEC~50~(triazolam): 16 μ[M]{.smallcaps} (cRNA ratio α1:β2:γ2S 1:1:1), 24 μ[M]{.smallcaps} (1:1:3), 50 μ[M]{.smallcaps} (1:1:10; [Figure 1a](#fig1){ref-type="fig"}, see also legend to [Figure 1](#fig1){ref-type="fig"} for individual EC~50~ values).

The typical pattern of *I*~GABA~ modulation of an oocyte (α1:β2:γ2S cRNA ratio 1:1:3) is illustrated in [Figure 1b](#fig1){ref-type="fig"}. Triazolam enhanced *I*~GABA~ predominantly at low GABA concentrations corresponding to EC~5−10~ (concentrations of GABA that induce 5--10% of maximal GABA-evoked current) and had almost no effects at a saturating GABA concentration. Similar observations were made for α1β2γ1 receptors ([Figure 1c](#fig1){ref-type="fig"}).

Different efficiencies of *I*~GABA~ potentiation in oocytes expressing α1β2γ1 or α1β2γ2S receptors
--------------------------------------------------------------------------------------------------

[Figure 1](#fig1){ref-type="fig"} illustrates that GABA potency (EC~50~) and *I*~GABA~ modulation by triazolam were both dependent on the amount of γ2S (or γ1) incorporation (see also [Boileau *et al*., 2002](#bib10){ref-type="other"}). These experiments confirmed that apparent higher γ-expression and correspondingly lower GABA sensitivity were always associated with larger BZD-induced shifts of the curves. In line with [Boileau *et al*. (2002](#bib10){ref-type="other"}, [2003)](#bib12){ref-type="other"} we observed a higher GABA sensitivity at cRNA ratios 1:1:1 and 1:1:3 compared to 1:1:10. The range of GABA EC~50~s for a given cRNA ratio reflected differences in γ-incorporations.

EC~50~s of individual oocytes were plotted versus the BZD-induced shifts of the GABA concentration--response curves (ΔEC~50~(BZD)s; [Figure 2](#fig2){ref-type="fig"}). For all three compounds applied at saturating concentrations, we obtained a clear correlation between EC~50~s and ΔEC~50~(BZD)s. The slope factors for oocytes expressing α1β2γ1 subunit receptors (1.8±0.1 (triazolam; [Figure 2a](#fig2){ref-type="fig"}), 1.6±0.1 (clotiazepam; [Figure 2b](#fig2){ref-type="fig"}) and 2.3±0.2 (midazolam; [Figure 2c](#fig2){ref-type="fig"})) were always higher than for oocytes expressing α1β2γ2S receptors (1.4±0.1 (triazolam; [Figure 2d](#fig2){ref-type="fig"}), 1.4±0.1 (clotiazepam; [Figure 2e](#fig2){ref-type="fig"}) and 1.3±0.1 (midazolam; [Figure 2f](#fig2){ref-type="fig"})). The regression line approached the ordinate in the range of the EC~50~ of α1β2 receptors. The data suggest that the slope factors may reflect the efficiency of *I*~GABA~ potentiation for these compounds (see [Table 1](#tbl1){ref-type="table"}). For clotiazepam, we estimated similar slopes for γ1- and γ2S-incorporating receptors (difference statistically not significant; *P*\>0.05) whereas for triazolam and midazolam the slopes of the regression lines for the two receptor subtypes were significantly different (*P*\<0.05).

Pharmacological properties of concatenated subunits fit the extrapolated regression lines
-----------------------------------------------------------------------------------------

If the inhibition of GABA sensitivity caused by γ-incorporation correlates with *I*~GABA~ potentiation, then complete γ-incorporation in concatenated subunits is expected to result in larger EC~50~s. To test this hypothesis we first injected higher amounts of γ1 and γ2S subunit cRNA (1:1:20; see [Figure 3](#fig3){ref-type="fig"}). We obtained, however, only a non-significant (*P*\<0.05) further reduction in GABA sensitivity (α1β2γ1: EC~50~=61±3 μ[M]{.smallcaps}, *n*=4 and α1β2γ2S: EC~50~=62±4 μ[M]{.smallcaps}, *n*=4, see dashed lines in [Figure 3](#fig3){ref-type="fig"}). Next we expressed a mixture of concatenated subunit constructs (γ2-β2-α1 and β2-α1, 1:1 ratio; [Baumann *et al*., 2002](#bib7){ref-type="other"}) and analysed the GABA concentration--response curves. [Figure 3](#fig3){ref-type="fig"} compares the mean GABA concentration--response curves obtained for oocytes injected with cRNAs for α1β2 (1:1, *n*=6), α1β2γ1 (1:1:10, *n*=24), α1β2γ1 (1:1:20, *n*=4), α1β2γ2S (1:1:10, *n*=27), α1β2γ2S (1:1:20, *n*=4) or concatenated γ2-β2-α1/β2-α1 receptors (1:1, *n*=18). In line with previous studies ([Baumann *et al*., 2002](#bib7){ref-type="other"}) oocytes expressing concatenated subunits in *Xenopus* oocytes displayed a lower GABA sensitivity. The EC~50~ of concatenated subunits was substantially shifted to the right (EC~50~=186±13 μ[M]{.smallcaps}, *n*=18; [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). The EC~50~s and corresponding shifts of the concentration--response curve (ΔEC~50~(BZD)s) for all three compounds are shown in [Figures 4a--c](#fig4){ref-type="fig"}. When EC~50~s and corresponding ΔEC~50~(BZD)s were added to the graph shown in [Figure 2](#fig2){ref-type="fig"} ([Figures 4d--f](#fig4){ref-type="fig"}) they fitted the extended linear correlation obtained for non-concatenated subunits.

Estimation of α1β2 and α1β2γ2S receptor fractions
-------------------------------------------------

In an independent approach we theoretically calculated the behaviour of a mixed population of GABA~A~ receptors with a high (α1β2) and a low (α1β2γ2S) GABA sensitivity. The total normalized *I*~GABA~ is the weighted sum of partial current responses of the individual receptors and only α1β2γ2S are sensitive to BZDs (see Materials and methods). The simulated curves are shown in [Figure 4](#fig4){ref-type="fig"} (solid lines). To calculate the putative fractions of α1β2 and α1β2γ2S receptors for oocytes displaying different GABA sensitivities we made use of the concentration of half-maximal activation of the simulated curve of αβ receptors (EC~50,α1β2~=8±2 μ[M]{.smallcaps}, *n*=6; see also [Sigel and Baur, 2000](#bib35){ref-type="other"}; [Baumann *et al*., 2001](#bib6){ref-type="other"}) and EC~50,α1β2γ2S~ (186 μ[M]{.smallcaps}) of concatenated receptors and corresponding Hill coefficients (*H*~α1β2~=1.0, *H*~α1β2γ2S~=1.3) from our experiments (see [Figure 3](#fig3){ref-type="fig"}).

The maximum likelihood fit of the EC~50~ versus ΔEC~50~ relation predicts 100% γ2S incorporation for the concatenated receptors ([Figures 4d--f](#fig4){ref-type="fig"}). Our calculations suggest, however, that even at a 1:1:10 cRNA ratio the fraction (*F*) of current through α1β2γ2S receptors accounts for only between 50 and 70% of the total current. If we assume that the single channel currents through γ incorporating receptors is *n* times larger than through α1β2 receptors, then the fraction (*f*) of γ incorporating receptors is given by *f*=*F*/(*n*−*F*(1−*n*)).

This formula accounts for differences in single channel conductance. The frequency of openings and mean open time also influences mean conductance of both subpopulations. The equation describing concentration--response curve used in our calculation (see Materials and methods) estimates the fraction of open channels that in turn reflects the mean open time of single channels at different GABA concentrations and thus accounts for differences in open time. Assuming a twofold greater single channel conductance for α1β2γ2S receptors (that is, *n*=2, see [Angelotti and Macdonald, 1993](#bib3){ref-type="other"}; [Fisher and Macdonald, 1997](#bib20){ref-type="other"}) and *F*≈70% would predict *f*≈54%. In other words, our analysis suggests that even under conditions where α1:β2:γ2S were injected at a ratio of 1:1:10 only about 50% of the expressed receptors contain a γ2S subunit. This may explain the large difference in EC~50~s of concatenated and non-concatenated receptors (even at a ratio of 1:1:20; [Figure 3](#fig3){ref-type="fig"}).

Relation between EC~50~ and ΔEC~50~(BZD) on a GABA~A~ receptor mutant with reduced GABA sensitivity
---------------------------------------------------------------------------------------------------

Larger slope factors of γ1- versus lower slope factors of γ2S-containing receptors indicated that this parameter provides a measure of drug efficiency. To further validate the sensitivity of this parameter, we made use of a mutation (β2-R207C; located in the GABA-binding site), known to induce a reduction in GABA sensitivity (see also [Wagner and Czajkowski, 2001](#bib40){ref-type="other"}; [Wagner *et al*., 2004](#bib41){ref-type="other"}). GABA~A~ receptors composed of α1 and β2-R207C subunits displayed a reduced GABA sensitivity ([Figure 5a](#fig5){ref-type="fig"}; EC~50~ for α1β2-R207C=486±81 μ[M]{.smallcaps}, *n*=6; see also [Wagner *et al*., 2004](#bib41){ref-type="other"}). Co-expression of α1, β2-R207C with the γ2S subunit induced a further reduction of GABA sensitivity ([Figure 5a](#fig5){ref-type="fig"}; EC~50~ for α1β2-R207Cγ2S=3217±378 μ[M]{.smallcaps}, *n*=18). A saturating concentration of clotiazepam (10 μ[M]{.smallcaps}) significantly increased chloride currents at GABA EC~5−10~ ([Figure 5b](#fig5){ref-type="fig"}). The corresponding correlation between individual EC~50~ values of the GABA concentration--response curves (EC~50~s) of oocytes expressing α1β2-R207Cγ2S receptors and shifts of these EC~50~ values (ΔEC~50~(BZD)s) caused by three BZDs is shown in [Figures 6d--f](#fig6){ref-type="fig"}. The regression lines approach the EC~50~ axis in a range (460--587 μ[M]{.smallcaps}; [Figures 6d--f](#fig6){ref-type="fig"}) close to the EC~50~ of α1β2-R207C receptors ([Figure 5a](#fig5){ref-type="fig"}). [Figures 6a--c](#fig6){ref-type="fig"} illustrate typical shifts of the dose--response curves by a saturating concentration of triazolam (1 μ[M]{.smallcaps}) for different α1:β2-R207C:γ2S cRNA ratios (1:1:1---ΔEC~50~=421 μ[M]{.smallcaps}, (a); 1:1:3---ΔEC~50~=948 μ[M]{.smallcaps}, (b) and 1:1:10---ΔEC~50~=2900 μ[M]{.smallcaps}, (c); see also legend to [Figure 6](#fig6){ref-type="fig"} for individual EC~50~ values). The slopes of regression lines were 1.1±0.1 (triazolam), 1.1±0.1 (clotiazepam) and 1.2±0.1 (midazolam). Interestingly, the three BZDs enhanced *I*~GABA~ at saturating GABA concentrations (10--100 m[M]{.smallcaps}) where peak currents in wild-type receptors were hardly affected (compare triazolam action in [Figures 1](#fig1){ref-type="fig"} and [6](#fig6){ref-type="fig"}).

Discussion
==========

This study revealed a linear correlation between the γ-subunit-mediated suppression and BZD-induced increase of GABA sensitivity in α1β2γ2S and α1β2γ1 receptors. We made use of a statistical approach because direct evaluation of this relationship is complicated by variable γ-incorporation even under conditions where high ratios of γ-subunit cRNA relative to α1 and β2 are injected. Injection of higher cRNA ratio of α1:β2:γ2S than 1:1:10 induced only a slight further reduction in GABA sensitivity suggesting a non-linear relationship between cRNA ratios and γ-subunit incorporation (see 1:1:20 ratio in [Figure 3](#fig3){ref-type="fig"} and also [Boileau *et al*., 2002](#bib10){ref-type="other"}). We have therefore induced different γ-expression by injecting different cRNA ratios and analysed the relation between γ-mediated inhibition and BZD-induced enhancement of GABA sensitivity.

Slopes of regression lines are inversely related to BZD efficiency
------------------------------------------------------------------

An initially observed trend that larger BZD induced shifts of the concentration--response curves (ΔEC~50~(BZD)s) in oocytes expressing larger fractions of γ-subunit-containing receptors (induced by injection of increasing amounts of cRNA encoding for γ-subunits, [Figure 1](#fig1){ref-type="fig"}) was confirmed by correlation analysis ([Figure 2](#fig2){ref-type="fig"}). The linear relationship between EC~50~ values and ΔEC~50~(BZD) suggests that BZDs reduce a γ-subunit-mediated inhibition of GABA sensitivity. A slope of 1.0 would correspond to complete elimination of a γ-subunit-induced inhibition of GABA sensitivity and BZDs would correspondingly shift the concentration--response curve of α1β2γ1(2S) receptors to the position of α1β2 receptors. The observation that the tested BZDs never increased GABA sensitivity to that or above that of α1β2 receptors indicates that these drugs only partially can compensate for the γ-subunit-induced inhibition.

The estimated slope factors ranged from 1.1±0.1 in α1β2-R207Cγ2S (triazolam, clotiazepam) to 2.3±0.2 (midazolam) in α1β2γ1 subunit receptors. To evaluate the significance of the slopes we compared the slopes on oocytes expressing α1β2γ1 and α1β2γ2S subunit receptors. The present results support previously estimated maximal *I*~GABA~ potentiation by midazolam (342±64%)\>clotiazepam (260±27%)≈triazolam (253±12%) for oocytes expressing α1β2γ2S receptors ([Khom *et al*., 2006](#bib24){ref-type="other"}) and indicate a reversed order of regression slopes (midazolam: 1.3±0.1\<clotiazepam: 1.4±0.1=triazolam: 1.4±0.1). Furthermore, steeper slopes of the regression lines for α1β2γ1 compared to α1β2γ2S receptors specify that midazolam and to a lesser extent triazolam and clotiazepam increase GABA sensitivity less efficiently in α1β2γ1 than in α1β2γ2S receptors ([Figure 2](#fig2){ref-type="fig"}), which confirms our previous studies ([Khom *et al*., 2006](#bib24){ref-type="other"}). Taken together our data suggest that the slopes of the regression lines between ΔEC~50~(BZD)s and EC~50~s are inversely related to drug efficiency.

The described approach is time consuming as it requires the injection of different cRNA ratios and the measurements of a large number of concentration--response curves. Our experiments under different conditions (including different BZDs, γ-subunits and a mutation in the β2 subunit; [Figures 2](#fig2){ref-type="fig"}, [4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}) revealed, however, that the regression lines intercept the *y*-axis close to the EC~50~ of α1β2 receptors. This finding prompted us to evaluate the possibility to use the *y*-intercept and three randomly selected data points (cRNA ratio 1:1:10; [Figures 2d--f](#fig2){ref-type="fig"}) for correlation analysis. The simplified procedure yielded regression lines with slopes that were statistically not significantly different from larger data sets (data not shown).

The relevance of the slope factor was further evaluated making use of the mutation β2-R207C that is known to induce a more than 60-fold reduction in GABA sensitivity ([Wagner *et al*., 2004](#bib41){ref-type="other"}). [Figure 5a](#fig5){ref-type="fig"} illustrates that co-expression of γ2S decreased the GABA sensitivity analogously to wild-type receptors ([Figure 3](#fig3){ref-type="fig"}). The estimated slope factors (1.1±0.1 (triazolam), 1.1±0.1 (clotiazepam) and 1.2±0.1 (midazolam); [Figure 6](#fig6){ref-type="fig"}) were always smaller than in wild type (though only in the case of triazolam and clotiazepam that difference was significant, *P*\<0.05), suggesting even higher BZD efficiencies compared to wild type.

Concatenated receptor subunits fit the regression lines
-------------------------------------------------------

Forced γ2 subunit incorporation in oocytes was previously shown to be associated with a significant loss in GABA sensitivity compared to oocytes injected with 1:1:10 cRNA ratios ([Baumann *et al*., 2002](#bib7){ref-type="other"}; see also [Figure 3](#fig3){ref-type="fig"}; but see [Baur *et al*., 2006](#bib8){ref-type="other"}). Here we show that the higher EC~50~s and corresponding ΔEC~50~(BZD)s of concatenated subunits fit the predictions of the regression lines of non-concatenated subunits ([Figures 4d--f](#fig4){ref-type="fig"}, closed triangles). The mean EC~50~ of the concatenated γ2-β2-α1/β2-α1 subunits ([Figure 3](#fig3){ref-type="fig"}) corresponds to the data of [Baumann *et al*. (2002)](#bib7){ref-type="other"}. Lower GABA sensitivity and higher BZD efficiencies of concatenated subunits expressed in *Xenopus* oocytes may accordingly result from more complete γ-incorporation (rather than from forced subunit arrangement or interactions). Our data suggest that the studied GABA~A~ receptor composed of two concatenated constructs may represent a model of completely assembled receptor with intact GABA- and BZD-binding sites. This hypothesis (based on the extrapolation of the regression line; [Figure 4](#fig4){ref-type="fig"}) requires, however, further studies.

These experimental data could be reproduced by a mathematical model describing BZD modulation in oocytes expressing different current fractions of high GABA sensitive α1β2 versus low-sensitive α1β2γ2S receptors. Maximum likelihood analysis predicted (in line with the experimental observations) a linear relationship that enables the calculation of a putative fraction of α1β2γ2S receptors at a given EC~50~ and ΔEC~50~(BZD). This calculation had, however, to account for the different single channel conductance of the two receptor subtypes ([Angelotti and Macdonald, 1993](#bib3){ref-type="other"}; [Fisher and Macdonald, 1997](#bib20){ref-type="other"}). Interestingly these independent calculations reproduced not only the linear correlation but predicted the expected 100% γ2S incorporation for the concatemers and thus would support the experimental findings of the concatenated receptors and our conclusions.

Percentage of α1β2γ2 receptors in oocytes expressing these subunits
-------------------------------------------------------------------

[Boileau *et al*. (2002)](#bib10){ref-type="other"} have clearly demonstrated that injecting higher ratios of γ2 subunit cRNA results in a purer population of α1β2γ2 subunit receptors. In addition, they observed a remarkable run-down of BZD modulation, suggesting a decay of γ2 subunit-incorporating receptors over time after injection into oocytes that makes it difficult to compare data from different labs. Furthermore, small changes in the applied effective GABA concentration (usually between EC~3~ and EC~10~) can substantially affect the apparent BZD efficiency, thus further confounding a calculation of the percentage of expressed α1β2γ2S receptors. The method suggested above for determining the slope of the regression line, however, also allows the determination of the percentage of α1β2γ2S receptors. After correction for single channel conductances (assuming a twofold difference in the single channel conductance of α1β2 and α1β2γ2S receptors, [Angelotti and Macdonald, 1993](#bib3){ref-type="other"}; [Fisher and Macdonald, 1997](#bib20){ref-type="other"}), a 70% current ratio would correspond to about 50% of γ2S subunit incorporation.

The regression slopes are independent from variations in expression of α1β2 versus α1β2γ2S(γ1) fractions or variations in experimental conditions (GABA concentration). The statistical analysis described here is based on the different shifts of the concentration--response curves and, therefore, independent of these possible experimental errors. The low percentage of α1β2γ2S receptors formed under the conditions used indicate that at least in the *Xenopus* oocyte system (but not necessarily in other heterologous expression systems or under native conditions) the efficiency of assembly of α1β2 receptors might be comparable to or even higher than that of α1β2γ2S receptors, resulting in comparable amounts of α1β2 or α1β2γ2S receptors even when high concentrations of γ-subunits are available.

Implications for the mechanism of BZD action
--------------------------------------------

The different shifts in the GABA concentration--response curves for GABA~A~ receptors with different subunit compositions or mutants can be interpreted in terms of a mechanism where BZDs increase the microscopic affinity of the GABA-binding site or, alternatively, by a mechanism where BZDs facilitate channel gating (for example, [Jones-Davis *et al*., 2005](#bib23){ref-type="other"}). The second scenario is supported by previous findings suggesting that BZD-like modulators enhance the amplitude of the GABA response by stabilizing the open channel conformation ([Downing *et al*., 2005](#bib16){ref-type="other"}; [Rusch and Forman, 2005](#bib31){ref-type="other"}; [Campo-Soria *et al*., 2006](#bib14){ref-type="other"}).

We are tempted to speculate that the BZD-induced *I*~GABA~ increase reflects an increase in GABA efficacy (as defined by [Colquhoun, 1998](#bib15){ref-type="other"}) by a direct transduction of the BZD effect to the channel region ([Akabas, 2004](#bib1){ref-type="other"}; [Ernst *et al*., 2005](#bib18){ref-type="other"}). An increase of efficacy from apparent low level (for example, in mutant β2-R207C or concatemers) could explain an increase of the maximal GABA response ('over-potentiation\' of the BZDs on the α1β2-R207Cγ2S isoform or concatenated receptors) and a simultaneous shift of the concentration--response curve ([Figures 4a--c](#fig4){ref-type="fig"} and [6a--c](#fig6){ref-type="fig"}; [Colquhoun, 1998](#bib15){ref-type="other"}; [Downing *et al*., 2005](#bib16){ref-type="other"}; [Rusch and Forman, 2005](#bib31){ref-type="other"}; [Campo-Soria *et al*., 2006](#bib14){ref-type="other"}). These theoretical considerations need, however, more experimental validation including the investigation of further mutations (for example, in the putative GABA-binding site and/or pore region) and the use of BZDs with a broad range of efficiencies.
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![(**a**) Typical GABA concentration--response curves of oocytes injected with cRNAs of α1, β2 and γ2S subunits (cRNA stoichiometry: 1:1:1, left panel; 1:1:3, middle panel and 1:1:10, right panel) in the absence (control) and presence of 1 μ[M]{.smallcaps} triazolam. The corresponding EC~50~ values for 1:1:1 were 24 μ[M]{.smallcaps} (control), 8 μ[M]{.smallcaps} (triazolam); for 1:1:3: 38 μ[M]{.smallcaps} (control), 14 μ[M]{.smallcaps} (triazolam) and for 1:1:10: 71 μ[M]{.smallcaps} (control), 21 μ[M]{.smallcaps} (triazolam). (**b**) Corresponding *I*~GABA~ through α1β2γ2S (1:1:3) channels modulated by 1 μ[M]{.smallcaps} triazolam at indicated GABA concentrations. (**c**) GABA concentration--response curves of oocytes injected with cRNAs of α1, β2 and γ1 subunits (1:1:1, left panel; 1:1:3, middle panel and 1:1:10, right panel) in the absence (control) and presence of 1 μ[M]{.smallcaps} triazolam. The corresponding EC~50~ values for 1:1:1 were: 21 μ[M]{.smallcaps} (control), 12 μ[M]{.smallcaps} (triazolam); for 1:1:3: 31 μ[M]{.smallcaps} (control), 16 μ[M]{.smallcaps} (triazolam); for 1:1:10: 66 μ[M]{.smallcaps} (control), 29 μ[M]{.smallcaps} (triazolam). Each graph in (**a**) and (**c**) represents one experiment on one oocyte.](bjp2008271f1){#fig1}

![Correlation between EC~50~ values of the GABA concentration--response curves (EC~50~s) of oocytes expressing α1β2γ1 receptors (**a**--**c**), α1β2γ2S receptors (**d**--**f**) and shifts of these EC~50~ values (ΔEC~50~(BZD)s) by modulation of the GABA concentration--response curve by 1 μ[M]{.smallcaps} triazolam (**a**, **d**), 10 μ[M]{.smallcaps} clotiazepam (**b**, **e**) and 10 μ[M]{.smallcaps} midazolam (**c**, **f**); α-, β- and γ-subunit cRNA stoichiometries are 1:1:1, 1:1:3 and 1:1:10. Correlation coefficients were 0.94 (triazolam), 0.94 (clotiazepam), 0.94 (midazolam) (*P*\<0.0001 in all cases, α1β2γ1) and 0.97 (triazolam), 0.94 (clotiazepam), 0.90 (midazolam) (*P*\<0.0001 in all cases, α1β2γ2S). Each data point represents one experiment on one oocyte.](bjp2008271f2){#fig2}

![GABA concentration--response curves for oocytes expressing α1β2 (cRNA injection 1:1), α1β2γ1 (1:1:10), α1β2γ1 (1:1:20), α1β2γ2S (1:1:10), α1β2γ2S (1:1:20) and γ2-β2-α1/β2-α1 (1:1) receptors. The corresponding mean EC~50~ values and Hill coefficients were α1β2 (1:1): 8±2 μ[M]{.smallcaps}, *n*~H~=1.0±0.2 (*n*=6); α1β2γ1 (1:1:10): 48±3 μ[M]{.smallcaps}, *n*~H~=1.3±0.1 (*n*=24); α1β2γ1 (1:1:20): 61±3 μ[M]{.smallcaps}, *n*~H~=1.5±0.1 (*n*=4); α1β2γ2S (1:1:10): 51±3 μ[M]{.smallcaps}, *n*~H~=1.4±0.1 (*n*=27); α1β2γ2S (1:1:20): 62±4 μ[M]{.smallcaps}, *n*~H~=1.5±0.1 (*n*=4); γ2-β2-α1/β2-α1 (1:1): 186±13 μ[M]{.smallcaps}, *n*~H~=1.3±0.1 (*n*=18).](bjp2008271f3){#fig3}

![GABA concentration--response curves of oocytes injected with concatenated subunits (γ2-β2-α1/β2-α1) in the absence (control) and presence of 1 μ[M]{.smallcaps} triazolam (**a**), 10 μ[M]{.smallcaps} clotiazepam (**b**) and 10 μ[M]{.smallcaps} midazolam (**c**). The corresponding EC~50~ values were: 158 μ[M]{.smallcaps} (control), 34 μ[M]{.smallcaps} (triazolam); 150 μ[M]{.smallcaps} (control), 60 μ[M]{.smallcaps} (clotiazepam); 132 μ[M]{.smallcaps} (control), 43 μ[M]{.smallcaps} (midazolam). EC~50~ values of the GABA concentration--response curves of oocytes expressing concatenated subunit constructs (γ2-β2-α1 and β2-α1 in 1:1 ratio) and ΔEC~50~(BZD)s induced by (**d**) 1 μ[M]{.smallcaps} triazolam, (**e**) 10 μ[M]{.smallcaps} clotiazepam and (**f**) 10 μ[M]{.smallcaps} midazolam were added to the regression lines from [Figures 2d--f](#fig2){ref-type="fig"}. Corresponding regression lines (dashed) were taken from [Figures 2d--f](#fig2){ref-type="fig"} and extended towards the values of the concatenated subunits. Solid lines (**d**--**f**) represent the non-linear fit of Equations 1--5 (see Materials and methods) by the maximal likelihood. Calculated current fractions of γ-incorporating receptors (0, 50, 70 and 100%) are indicated. Each graph (**a**, **b** and **c**) and each data point (**d**, **e** and **f**) represent one experiment on one oocyte.](bjp2008271f4){#fig4}

![(**a**) GABA concentration--response curves of oocytes expressing α1β2-R207C (1:1, EC~50~=486±81 μ[M]{.smallcaps}, *n*~H~=1.2±0.2, *n*=6) and α1β2-R207Cγ2S (1:1:10, EC~50~=3217±378 μ[M]{.smallcaps}, *n*~H~=0.9±0.1, *n*=18) receptors. (**b**) Representative traces for enhancement of *I*~GABA~ through α1β2-R207Cγ2S. Control currents (GABA) in the absence of clotiazepam and corresponding currents elicited by co-application of GABA and clotiazepam are shown.](bjp2008271f5){#fig5}

![GABA concentration--response curves of oocytes injected with cRNA ratios of α1, β2-R207C and γ2S subunits of 1:1:1 (**a**), 1:1:3 (**b**) and 1:1:10 (**c**) in the absence (control) and presence of 1 μ[M]{.smallcaps} triazolam. The corresponding EC~50~ values for 1:1:1 were: 827 μ[M]{.smallcaps} (control), 406 μ[M]{.smallcaps} (triazolam); for 1:1:3: 1945 μ[M]{.smallcaps} (control), 997 μ[M]{.smallcaps} (triazolam); for 1:1:10: 3891 μ[M]{.smallcaps} (control), 991 μ[M]{.smallcaps} (triazolam). (**d**--**f**) Correlation between individual EC~50~ values of the GABA concentration--response curves (EC~50~s) of oocytes expressing α1β2-R207Cγ2S receptors and shifts of these EC~50~ values (ΔEC~50~(BZD)s) caused by modulation of the GABA concentration--response curve by 1 μ[M]{.smallcaps} triazolam (**d**), 10 μ[M]{.smallcaps} clotiazepam (**e**) and 10 μ[M]{.smallcaps} midazolam (**f**). The slopes of regression lines were 1.1±0.1 (triazolam), 1.1±0.1 (clotiazepam) and 1.2±0.1 (midazolam). Correlation coefficients were 0.96 (triazolam), 0.98 (clotiazepam), 0.97 (midazolam) (*P*\<0.0001 in all cases). Each graph (**a**, **b** and **c**) and each data point (**d**, **e** and **f**) represent one experiment on one oocyte.](bjp2008271f6){#fig6}

###### 

Comparison of slope factors and maximal potentiation by BZDs

  *BZD*         *α1β2γ1*   *α1β2γ2S*             
  ------------- ---------- ----------- --------- --------
  Triazolam     1.8±0.1    85±7        1.4±0.1   253±12
  Clotiazepam   1.6±0.1    172±24      1.4±0.1   260±27
  Midazolam     2.3±0.2    92±8        1.3±0.1   342±64

Abbreviations: BZD, benzodiazepine; *I*~GABA~, GABA-activated chloride currents.

Data from [Khom *et al*. (2006)](#bib24){ref-type="other"}.
